EARNINGS (LOSS) PER SHARE

3 Months Ended

Mar. 31, 2023

Basic and diluted loss per share attributable to Bausch Health Companies Inc. were calculated as follows:


	Three Months Ended March 31,
(in millions, except per share amounts)		2023		2022
Net loss attributable to Bausch Health Companies Inc.		$	(201)	$	(69)
Basic and diluted weighted-average common shares outstanding		363.3		360.8


Basic and diluted loss per share attributable to Bausch Health Companies Inc.		$	(0.55)	$	(0.19)

During the three months ended March 31, 2023 and 2022, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been approximately 3,426,000 and 3,600,000 common shares for the three months ended March 31, 2023 and 2022, respectively.During the three months ended March 31, 2023 and 2022, time-based RSUs, performance-based RSUs and stock options to purchase approximately 17,636,000 and 9,332,000 common shares, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During the three months ended March 31, 2023 and 2022, an additional 90,000 and 156,000 performance-based RSUs, respectively, were not included in the computation of diluted earnings per share as the required performance conditions had not been met.